Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2972286 | 0.90 | LTA4H (0.50) | LTA4HHTR1AHTR7ALDH1A1 | |
| SCHEMBL2983973 | 0.84 | SIGMAR1 (0.51) | LTA4HHTR1ADRD2HTR7ALDH1A1 | |
| SCHEMBL2982171 | 0.81 | HTR2A (0.52) | LTA4HHTR1ADRD2HTR7CACNA1G | |
| SCHEMBL3594530 | 0.76 | LTA4H (0.53) | LTA4HHTR1ADRD2HTR7HTR6 | |
| SCHEMBL2981930 | 0.76 | DRD3 (0.46) | LTA4HHTR7HTR2A | |
| SCHEMBL2983168 | 0.75 | CCR8 (0.52) | KDM4E | |
| SCHEMBL3594531 | 0.74 | HTR2A (0.53) | LTA4HHTR1ADRD2HTR7HTR6 | |
| SCHEMBL9450196 | 0.74 | HTR2A (0.50) | LTA4HHTR1ADRD2HTR7CACNA1G | |
| SCHEMBL2974123 | 0.73 | LTA4H (0.45) | LTA4HHTR1ADRD2HTR7HTR6 | |
| SCHEMBL2975084 | 0.73 | CACNA1G (0.41) | CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781590-B2 | Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | LTA4H 19/4885HTR1A 893/4885DRD2 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.